Articles Tagged With: Pharmacology
-
Orthopedic Surgeons Say ‘Open-Label’ Placebos Are Ethical, Yet Few Use Them
-
Fluvoxamine Reduces the Risk for Hospitalization from COVID-19
Researchers found fluvoxamine (100 mg twice a day for 10 days) lowered the risk for hospitalization among high-risk outpatients diagnosed with COVID-19.
-
AAN Offers Ethical Guidance on Alzheimer’s Drug
Neurology experts issue caution on costs, side effects regarding the approved-but-controversial Aduhelm.
-
Finerenone Tablets (Kerendia)
Finerenone can be prescribed to lower the risk of sustained estimated glomerular filtration rate decline, cardiovascular death, non-fatal myocardial infarction, end-stage kidney disease, and hospitalization from heart failure in adults with chronic kidney disease associated with type 2 diabetes. -
Ethical Controversy Erupts Over Alzheimer’s Drug Approval
The first new Alzheimer’s drug to be approved in almost 20 years has sparked a major ethical controversy, leading to protest resignations, criticism, qualifying statements, and even calls for investigations. -
Anticoagulation Plus Antiplatelet Therapy in Chronic Atherosclerosis
An analysis of the COMPASS trial for the secondary endpoint of mortality showed the combination of low-dose rivaroxaban and aspirin significantly lowered the all-cause mortality rate vs. low-dose aspirin alone. -
Aducanumab-avwa Injection (Aduhelm)
The FDA has approved a new, but controversial, treatment for Alzheimer’s disease. -
The Effect of Antiviral Drugs on COVID-19 Outcomes and Mortality
The WHO Solidarity Trial Consortium found remdesivir, hydroxychloroquine, lopinavir, and interferon regimens produced “little or no effect” on relevant outcomes. -
Pegcetacoplan Injection (Empaveli)
The FDA has approved a new treatment for paroxysmal nocturnal hemoglobinuria, a rare, life-threatening blood disease. -
Time of the Essence with Dapagliflozin for Heart Failure
By adding dapagliflozin to maximally tolerated standard therapy for heart failure with reduced left ventricular ejection fraction, researchers noted the reduction in mortality and recurrent heart failure began within one month of starting this therapy.